[关键词]
[摘要]
目的 调查分析天津市海河医院收治的新型冠状病毒肺炎(COVID-19)确诊患者的临床分型及用药情况,为COVID-19抗病毒治疗药物的合理使用提供参考。方法 收集天津市海河医院2020年1月21日—2021年1月21日COVID-19患者抗病毒用药的销售量、销售金额等对用药频度(DDDs)、日均费用(DDC)、排序比(B/A)等指标进行统计分析。调查患者临床分型及抗病毒药物的使用方法,参考《新型冠状病毒肺炎诊疗方案》,评估抗病毒药物使用的合理性。结果 α2b干扰素销售金额最高、DDC最高、重型使用率最高;盐酸阿比多尔DDDs排序最高、药品排序比(B/A)比值>1,轻型、普通型、危重型使用率最高。经调查,医院抗病毒用药倾向于早期治疗。存在同时应用3种抗病毒药物和疗程>10 d的病例。结论 天津市海河医院以盐酸阿比多尔口服联合α2b干扰素雾化吸入构成基本用药。抗病毒药物使用率与临床分型密切相关。医院完全按照当时发行的《新型冠状病毒肺炎诊疗方案》的规定使用抗病毒药物并对抗病毒药物使用密切观察耐药性和不良反应的发生。
[Key word]
[Abstract]
Objective To investigate and analyze the clinical classification and medication status of confirmed COVID-19 patients admitted to Tianjin Haihe Hospital, providing reference for rational use of antiviral drugs for COVID-19.Method The sales volume and consumption sum of antiviral drugs for COVID-19 patients in Tianjin Haihe Hospital from January 21, 2020 to January 21, 2021 were collected for statistical analysis of DDDs, DDC, B/A and other indicators. Investigate the clinical classification of patients and the use of antiviral drugs, and evaluate the rationality of the use of antiviral drugs by referring to the COVID-19 Diagnosis and Treatment Protocol. Results The sales amount of interferon α2b was the highest, the DDC was the highest, and the heavy-duty usage rate was the highest. The DDDs of Arbidol hydrochloride was the highest, the drug sequencing ratio (B/A) ratio was > 1, and the utilization rate of light, general and critical type was the highest. After investigation, the hospital's antiviral drugs tend to be treated early. There are cases of simultaneous application of 3 antiviral drugs and a course of treatment > 10 d. Conclusion The hospital uses arbidol hydrochloride orally combined with α2b interferon nebulized inhalation to constitute the basic medication. The use rate of antiviral drugs is closely related to clinical classification. The hospital used antiviral drugs in accordance with the COVID-19 Diagnosis and Treatment Plan issued at that time and used antiviral drugs to closely observe the occurrence of drug resistance and adverse reactions.
[中图分类号]
R978.7
[基金项目]